Search results for "Administration"

showing 10 items of 5106 documents

US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioids Pros and Cons, and a European …

2012

Prescriptions for opioid analgesics to manage moderate-to-severe chronic non-cancer pain have increased markedly over the last decade. An unintentional consequence of greater prescription opioid utilization has been the parallel increase in misuse, abuse and overdose, which are serious risks associated with all opioid analgesics. In response to disturbing rises in prescription opioid abuse, the US Food and Drug Administration (FDA) has proposed the implementation of aggressive Risk Evaluation and Mitigation Strategies (REMS). While REMS could dramatically change the development, release, marketing and prescription of extended-release opioids, questions remain on how these programmes may inf…

medicine.medical_specialtyTime FactorsSettore MED/41 - AnestesiologiaLong-Acting Opioids Food and drug administration AnalgesiaRisk AssessmentFood and drug administrationPatient safetyPharmacotherapymedicineHumansPharmacology (medical)Medical prescriptionIntensive care medicineUnited States Food and Drug Administrationbusiness.industryPerspective (graphical)Chronic painLong-Acting Opioids Food and drug administration AnalgesiaOpioid-Related Disordersmedicine.diseaseUnited StatesRisk evaluationAnalgesics OpioidEuropeDelayed-Action PreparationsMedical emergencyChronic PainRisk assessmentbusiness
researchProduct

How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?

2009

The current approach for deciding the duration of vitamin K antagonist (VKA) treatment after an episode of venous thrombo-embolism (VTE) is mainly based on the characteristic of the index event (3 months or longer in case of unknown/persistent risk factors, 3 months or less in case of removable causes). However, the length of anticoagulation should be tailored on the patient's risk for recurrent thrombosis as well as for bleeding, but such 'time for decision' is often unclear and the optimal duration of VKA remains debatable. The presence of persistent residual vein thrombosis and increased D-dimer levels after stopping therapy are predictors for recurrent deep vein thrombosis (DVT). Manage…

medicine.medical_specialtyTime FactorsVitamin Kmedicine.drug_classDeep veinRisk AssessmentDrug Administration ScheduleRecurrent deep vein thrombosisSettore MED/15 - Malattie Del SangueFibrin Fibrinogen Degradation ProductsFibrinolytic AgentsRecurrenceNeoplasmsmedicineHumansVenous ThrombosisFirst episodebusiness.industryVascular diseaseAnticoagulantVitaminsHematologyVitamin K antagonistmedicine.diseaseThrombosisduration anticoagulants venous thromboembolismSurgeryVenous thrombosismedicine.anatomical_structurebusinessBiomarkersBritish Journal of Haematology
researchProduct

The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: a randomised, placebo-controlled, pilot study

2016

Aims Sex hormones could provide a future treatment avenue for dry eye post menopause. However, there are few well-controlled studies. This study investigates the impact of testosterone and oestrogen on dry eye symptoms and signs in postmenopausal women. Methods A randomised double-blind placebo-controlled pilot study was conducted involving 40 women with dry eye (age 63.9±5.1 years, 13.2±6.3 years post menopause). Ten women were assigned to each of four treatment groups: transdermal testosterone, oestradiol, testosterone/oestradiol combination and placebo. Assessment at baseline and after 8 weeks: ocular symptoms, tear osmolarity, tear stability, tear secretion, meibomian gland assessment, …

medicine.medical_specialtyTime Factorsmedicine.drug_classMeibomian glandPhysiologyPilot ProjectsAdministration CutaneousPlacebo03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compound0302 clinical medicineDehydroepiandrosterone sulfateDouble-Blind MethodInternal medicineHumansMedicineTestosteroneTear secretionRetrospective Studies030219 obstetrics & reproductive medicinebusiness.industryMeibomian GlandsEstrogensTestosterone (patch)Middle AgedAndrogeneye diseasesSensory SystemsPostmenopauseOphthalmologyTreatment Outcomemedicine.anatomical_structureEndocrinologychemistryTearsAndrogens030221 ophthalmology & optometryTearsDry Eye SyndromesFemalesense organsbusinessFollow-Up StudiesHormoneBritish Journal of Ophthalmology
researchProduct

Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia

2014

Oral administration of low-dose cyclophosphamide in pets with spontaneously occurring malignant neoplasms has become a common practice in veterinary medicine. The purpose of this retrospective study was to investigate toxicity events in cats with spontaneous malignancies receiving cyclophosphamide as a metronomic therapy for at least 1 month. The number and severity of clinical, haematological and biochemical adverse events were recorded according to the Veterinary Cooperative Oncology Group’s Common Terminology Criteria for Adverse Events v1.1 classification scheme. Twenty-four cats were enrolled in the study with a total number of 27 neoplasms: 13 sarcomas, 12 carcinomas, one melanoma an…

medicine.medical_specialtyToceranibCyclophosphamideCat DiseasesGastroenterologyDisease-Free SurvivalDrug Administration ScheduleMetastasisNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsSmall AnimalsAdverse effectAntineoplastic Agents AlkylatingCyclophosphamideNeoplasm StagingRetrospective StudiesCATSDose-Response Relationship Drugbusiness.industryCommon Terminology Criteria for Adverse Eventsmedicine.diseaseSurgeryThalidomideToxicityCatsbusinessmedicine.drugJournal of Feline Medicine and Surgery
researchProduct

A randomized clinical trial of topical dexamethasone vs. cyclosporine treatment for oral lichen planus

2021

BACKGROUND Oral lichen planus (OLP) is a common, frequently symptomatic, immune-mediated disease. Various treatments have been used for symptomatic OLP, including corticosteroids and immunosuppressants administered topically or systemically. The aim of this study was to compare the effectiveness of topical dexamethasone vs. topical cyclosporine in treatment of symptomatic OLP. MATERIAL AND METHODS Thirty-two patients with biopsy-proven symptomatic OLP were randomly assigned to two therapeutic groups: dexamethasone 2mg/5ml or cyclosporine 100mg/ml, both administered topically in a swish and spit method three times a day for 4 weeks. The patients were followed up for a total of 6 months. Asse…

medicine.medical_specialtyTopical dexamethasoneAdministration TopicalGastroenterologyDexamethasonelaw.inventionRandomized controlled triallawInternal medicinemedicine3-d printingHumansGeneral DentistryDexamethasoneUNESCO:CIENCIAS MÉDICASbusiness.industryorthognathic surgerysplintsmedicine.diseaseDysphagiaTreatment periodDiscontinuationClinical trialOtorhinolaryngologydata accuracyCyclosporineSurgeryOral lichen planusmedicine.symptombusinessImmunosuppressive Agentsmedicine.drugLichen Planus Oral
researchProduct

A common mechanism of action of the selective serotonin reuptake inhibitors citalopram and fluoxetine: Reversal of chronic psychosocial stress-induce…

2010

The transcription factor CREB regulates adaptive responses like memory consolidation, addiction, and synaptic refinement. Recently, chronic psychosocial stress as animal model of depression has been shown to stimulate CREB transcriptional activity in the brain; this stimulation was prevented by treatment with the antidepressant imipramine, which inhibits both noradrenaline and serotonin reuptake. However, it was unknown whether the selective inhibition of serotonin reuptake is sufficient for inhibition of stress-induced CREB activation, as it is for the clinical antidepressant effect. Therefore, the effect of two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, wa…

medicine.medical_specialtyTranscription GeneticMice TransgenicCitalopramBiologyCitalopramCREBImipramineDrug Administration ScheduleMice03 medical and health sciences0302 clinical medicineGenes ReporterCREB in cognitionFluoxetineInternal medicinemedicineAnimalsPhosphorylationCyclic AMP Response Element-Binding ProteinTranscription factor030304 developmental biologyPharmacology0303 health sciencesFluoxetineBrain3. Good healthEndocrinologyGene Expression RegulationMechanism of actionbiology.proteinAntidepressantmedicine.symptomSelective Serotonin Reuptake InhibitorsStress Psychological030217 neurology & neurosurgerymedicine.drugEuropean Journal of Pharmacology
researchProduct

Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis.

2012

Ocular inflammatory disorders constitute a sight-threatening group of diseases that might be managed according to their severity. Their treatment guidelines experience constant changes with new agents that improve the results obtained with former drugs. Nowadays we can make use of a five step protocol in which topical, periocular and systemic corticosteroids remain as the main therapy for non-infectious uveitis. In addition, immunosuppresive drugs can be added in order to enhance the anti-inflammatory effects and to play the role of corticosteroid-sparing agents. These can be organized in four other steps: cyclosporine and methotrexate in a second one; azathioprine, mycophenolate and tacrol…

medicine.medical_specialtyTreatment protocolCyclophosphamideAdministration TopicalImmunologyAnti-Inflammatory AgentsAzathioprineUveitisInfectious uveitisAdrenal Cortex HormonesmedicineImmunology and AllergyAnimalsHumansIntensive care medicinePharmacologyChlorambucilbusiness.industryTumor Necrosis Factor-alphaGeneral Medicinemedicine.diseaseTacrolimusSurgeryInjections IntravenousPractice Guidelines as TopicMethotrexateImmunotherapybusinessUveitisAlgorithmsImmunosuppressive Agentsmedicine.drugInflammationallergy drug targets
researchProduct

The use of topical corticosteroides in the treatment of oral lichen planus in Spain: A national survey

2017

Background Explore the treatment of oral lichen planus with topical corticosteroids by the healthcare professionals in Spain. Material and Methods A questionnaire targeted health professionals who treat OLP, in particular maxillofacial surgeons, dermatologist and dentist. The dissemination of the questionnaires was conducted through professional associations and dental and medical societies. The questionnaire was previously evaluated by means of a cognitive pre-test procedure to ensure that the questions were opportune and appropriate, understandable and acceptable among the professionals. Results Of the 890 questionnaires sent a total of 190 questionnaires were answered by 90 dentists, 60 …

medicine.medical_specialtyTriamcinolone acetonideAdministration TopicaleducationMEDLINEDentistry030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineCombined treatmentstomatognathic systemMedicineHumans030212 general & internal medicinePractice Patterns Physicians'skin and connective tissue diseasesGeneral DentistryGlucocorticoidsMaxillofacial surgeonsOral Medicine and Pathologyintegumentary systemHealth professionalsbusiness.industryResearch:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDermatologystomatognathic diseasesOtorhinolaryngologyTopical corticosteroidSpainHealth Care SurveysUNESCO::CIENCIAS MÉDICASSurgeryOral lichen planusTreatment timeSelf Reportbusinessmedicine.drugLichen Planus Oral
researchProduct

S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 2.

2019

The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology and pediatric rheumatology as well as policymakers and insurance funds. They were developed by dermatologists and pediatric dermatologists in collaboration with pediatric rheumatologists using a formal consensus process (S2k). The guidelines highlight topics such as disease severity, quality of life, treatment goals as well as problems associated with off-label drug therapy in children. Trigger factors and diagnostic aspects are discussed. The primary focus is on the various topical, systemic and UV-based treatment options available and includes recomm…

medicine.medical_specialtyTuberculosisAdolescentMEDLINEDermatologyDiseaseDrug Administration Schedule030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisBiological Factors0302 clinical medicinePharmacotherapyQuality of life (healthcare)PsoriasismedicineHumansPsoriasisChildBiosimilar PharmaceuticalsTonsillectomybusiness.industryVaccinationmedicine.diseaseSkin CareAnti-Bacterial AgentsFamily medicineUltraviolet TherapyDermatologic AgentsbusinessGuttate psoriasisImmunosuppressive AgentsJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGReferences
researchProduct

Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell…

1996

Objectives. To evaluate a selected population of 50 consecutive patients with primary T1, G3 bladder transitional cell carcinoma in the absence of carcinoma in situ (Tis) treated with a bladder-sparing approach. Methods. Between January 1983 and December 1992, all patients were treated by transurethral resection (TUR) plus adjuvant intravesical chemotherapy over 1 year. In most cases, doxorubicin, epirubicin, and mitomycin were used alone or in combination. Results. At a mean follow-up period of 52 months (range, 18 to 126), 16 of 50 patients (32%) showed a recurrent superficial tumor. The recurrent lesion was of Stage T1 in 11 (22%) cases, but was a T1, G3 tumor only in 5 cases (10%). In 2…

medicine.medical_specialtyUrologymedicine.medical_treatmentPopulationAntineoplastic AgentsMitomycinsSettore MED/24 - UrologiaCystectomyUrethraCarcinomamedicineHumansBACILLUS CALMETTE-GUERINeducationEpirubicinNeoplasm StagingCarcinoma Transitional Celleducation.field_of_studyUrinary bladderBladder cancerbusiness.industryCarcinoma in situmedicine.diseaseCombined Modality TherapyCANCERSurgeryAdministration Intravesicalmedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinSurgical Procedures OperativeNeoplasm Recurrence LocalbusinessFollow-Up StudiesEpirubicinmedicine.drugUrology
researchProduct